Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 FinancialNewsMedia - Thu Jun 20, 7:45AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
KYMR : 30.22 (-2.36%)
RHHBY : 34.4300 (-0.61%)
GILD : 68.40 (-0.35%)
AMGN : 310.77 (-0.08%)
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 GlobeNewswire - Thu Jun 20, 7:45AM CDT

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
KYMR : 30.22 (-2.36%)
RHHBY : 34.4300 (-0.61%)
GILD : 68.40 (-0.35%)
AMGN : 310.77 (-0.08%)
Why Shares of Kymera Therapeutics Jumped on Tuesday Motley Fool - Tue Oct 3, 2023

The company had a big bounce after hitting a 52-week low the day before.

SNY : 48.54 (-2.12%)
KYMR : 30.22 (-2.36%)
Join These Motley Fool Investors for "The Market Cap Game Show" Motley Fool - Sat Apr 1, 2023

Multiplying the number of shares by the share price is just step one.

ASML : 1,047.89 (+1.39%)
AMZN : 200.00 (+1.42%)
MELI : 1,596.48 (-0.07%)
ETSY : 58.26 (+2.19%)
PYPL : 58.97 (+2.01%)
CELH : 57.24 (-1.04%)
KYMR : 30.22 (-2.36%)
MA : 444.65 (+1.61%)
BOC : 12.92 (-0.39%)
PCOR : 67.98 (+2.70%)
WMT : 68.07 (+0.87%)
X-Chem and Kymera Expand Existing Partnership Business Wire - Tue Jan 31, 2023

X-Chem , the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc. (NASDAQ: KYMR). With the expanded...

KYMR : 30.22 (-2.36%)
Delta, Kymera rise; Charter, ABM Industries fall Associated Press - Wed Dec 14, 2022

Stocks that traded heavily or had substantial price changes Wednesday: Delta, Kymera rise; Charter, ABM Industries fall

ABM : 50.25 (+0.18%)
VSAT : 13.74 (+9.22%)
DAL : 46.71 (-0.45%)
CHTR : 303.50 (+2.53%)
MSFT : 459.28 (+0.56%)
KYMR : 30.22 (-2.36%)
LII : 536.00 (+2.34%)
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners Motley Fool - Wed Dec 14, 2022

Business wins are shining the spotlight on these two companies.

COMP : 3.53 (+5.06%)
$NASX : 18,028.76 (+0.84%)
KYMR : 30.22 (-2.36%)
RNA : 38.80 (-6.01%)
SNY : 48.54 (-2.12%)
Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update Globe Newswire - Tue Aug 9, 2022

Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated...

KYMR : 30.22 (-2.36%)
Kymera Therapeutics to Report Second Quarter 2022 Results on August 9 Globe Newswire - Wed Jul 27, 2022

WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing...

KYMR : 30.22 (-2.36%)
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan Globe Newswire - Fri Jul 8, 2022

WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing...

KYMR : 30.22 (-2.36%)

Barchart Exclusives

Is This Copper Mining Stock a Buy for Its Fat Dividend? Barchart - Tue Jul 2, 6:30PM CDT
Southern Copper has a higher dividend yield compared to other copper mining companies. However, its valuations are also on the higher side, making a closer examination of the risk-reward necessary for prospective investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot